Use of nail and oral pigmentation to determine ART eligibility among HIV-infected Ugandan adults

Trop Med Int Health. 2010 Feb;15(2):259-62. doi: 10.1111/j.1365-3156.2009.02448.x.

Abstract

Objectives: To evaluate the use of grey/distal banded nails as an indicator of advanced immunosuppression, and thus eligibility for ART, in resource poor settings.

Methods: We tested whether grey/distal banded nails and/or oral pigmentation could be used to identify patients with low CD4 cell counts at two cut-offs: <200 and <350 cells/microl in ART naive adults.

Results: Four hundred and three nail and oral cavities were photographed and assessed. Grey/distal banded nails and/or oral pigmentation were significantly associated with a CD4 cell count <200 cells/microl (P < 0.001), with a sensitivity of 66%, a specificity of 50% and a negative predictive value of 77%. However, there was no association when a CD4 cell count cut-off of <350 cells/microl was used. Inter-observer agreement (k 0.46) was fair/moderate.

Conclusions: While grey/distal banded nails and/or oral pigmentation are associated with low CD4 counts, the sensitivity and kappa score are too low for this method to be recommended as a tool to guide ART initiation; large number of individuals eligible for ART would be missed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV-1*
  • Humans
  • Hyperpigmentation / immunology
  • Hyperpigmentation / pathology
  • Hyperpigmentation / virology*
  • Immune Tolerance
  • Male
  • Mouth Diseases / immunology
  • Mouth Diseases / pathology
  • Mouth Diseases / virology*
  • Mouth Mucosa / pathology
  • Nail Diseases / immunology
  • Nail Diseases / pathology
  • Nail Diseases / virology*
  • Observer Variation
  • Patient Selection
  • Predictive Value of Tests
  • Sensitivity and Specificity

Substances

  • Anti-HIV Agents